A Phase 1, Randomized, Partially Double-Blind, Placebo- and Positive-Controlled, Parallel Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants

The purpose of this study is to evaluate the effect of povorcitinib on the QT/QTc Interval in healthy participants.

Start Date12 Jul 2024

Sponsor / Collaborator

Incyte Corp.

NCT06416800 / RecruitingPhase 1

An Open-Label Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants

The purpose of this study is to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics When Administered Orally to Healthy Adult Participants.

Start Date19 Jun 2024

Sponsor / Collaborator

Incyte Corp.

NCT06380205 / Active, not recruitingPhase 1

A Phase 1, Open-Label Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

The purpose of this study is to evaluate the drug interaction between povorcitinib and the oral contraceptive levonorgestrel/ethinyl estradiol in healthy adult females.

Start Date07 May 2024

Sponsor / Collaborator

Incyte Corp.

100 Clinical Results associated with Povorcitinib

100 Translational Medicine associated with Povorcitinib

100 Patents (Medical) associated with Povorcitinib

Literatures (Medical) associated with Povorcitinib

01 Jan 2024·American journal of clinical dermatology

Chronic Prurigo Including Prurigo Nodularis: New Insights and Treatments

Review

Author: Zeidler, Claudia ; Ständer, Sonja ; Müller, Svenja

Chronic prurigo (CPG) is a neuroinflammatory, fibrotic dermatosis that is defined by the presence of chronic pruritus (itch lasting longer than 6 weeks), scratch-associated pruriginous skin lesions and history of repeated scratching. Patients with CPG experience a significant psychological burden and a notable impairment in their quality of life. Chronic prurigo of nodular type (CNPG; synonym: prurigo nodularis) represents the most common subtype of CPG. As CNPG is representative for all CPG subtypes, we refer in this review to both CNPG and CPG. We provide an overview of the clinical characteristics and assessment of CPG, the burden of disease and the underlying pathophysiology including associated therapeutic targets. The information provided results from a PubMed search for the latest publications and a database search for current clinical trials (ClinicalTrials.gov, EU Clinical Trials Register [European Medicines Agency]; using the following terms or combinations of terms: 'chronic prurigo', 'prurigo', 'prurigo nodularis', 'pathophysiology', 'therapy', 'biologics', 'treatment'). Dupilumab is the first authorized systemic therapy by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for CNPG to date. Topical and systemic agents that are currently under investigation in clinical randomized, placebo-controlled phase II and III trials such as biologics (e.g., nemolizumab, vixarelimab/KPL-716, barzolvolimab/CDX-0159), small molecules (ruxolitinib cream, povorcitinib/INCB054707, abrocitinib) and the opioid modulator nalbuphine are highlighted. In the last past 15 years, several milestones have been reached regarding the disease understanding of CPG such as first transcriptomic analysis, first terminology, first guideline, and first therapy approval in 2022, which contributed to improved medical care of affected patients. The broad range of identified targets, current case observations and initiated trials offers the possibility of more drug approvals in the near future.

01 Jan 2024·International immunopharmacology

A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment

Review

Author: Sadeghi, Sara ; Ghane, Yekta ; Goodarzi, Azadeh ; Heidari, Amirhossein ; Heidari, Nazila

BACKGROUNDS AND AIMS:

Hidradenitis suppurativa (HS) is a challenging skin disease with an underlying inflammatory process. Substantial progress has been made in our understanding of HS over the last few years, with the advancement of novel treatment approaches. The current systematic review aims to evaluate the safety and efficacy of Janus kinase (JAK) inhibitors and spleen tyrosine kinase (Syk) inhibitors in treating HS.

METHOD:

A thorough systematic search was performed on PubMed/Medline, Web of Science, and Ovid Embase databases up to September 23th, 2023. Clinical studies published in English were included.

RESULTS:

Our search yielded ten articles with a total of 165 patients treated with four types of JAK inhibitors (upadacitinib, povorcitinib, tofacitinib, and baricitinib) and one Syk inhibitor (fostamatinib). Upadacitinib, povorcitinib, and tofacitinib improved clinical outcomes, with a significant reduction in hidradenitis suppurativa clinical response (HiSCR) and abscess and inflammatory nodule count (AN count) during the treatment period. Also, these drugs are well tolerated in most HS patients with minimal adverse events (AEs). Moreover, baricitinib depicted an amelioration in signs and symptoms of HS in one case report. Also, fostamatinib exhibited favorable tolerability throughout a 12-week in moderate-to-severe HS patients. The remarkable clinical improvement, as assessed through HiSCR and hidradenitis suppurativa severity (IHS4), corresponded closely with serological indicators of inflammation following fostamatinib administration was achieved.

CONCLUSION:

JAK and Syk inhibitors are potentially efficacious in managing moderate-to-severe HS since the proinflammatory cytokines are mediated by JAK and Syk signaling pathways. However, further research with a more rigorous examination is mandatory to evaluate such medication's long-term safety and efficacy.

01 Mar 2024·Journal of the American Academy of Dermatology

Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study

Article

Author: Kimball, Alexa B ; Brown, Kurt ; Wang, Annie ; Porter, Martina L ; Kirby, Joslyn S ; Okun, Martin M ; Alavi, Afsaneh ; Bechara, Falk G ; Zouboulis, Christos C ; Santos, Leandro L ; Bibeau, Kristen B

BACKGROUND:

Janus kinase 1 inhibition may alleviate hidradenitis suppurativa (HS)-associated inflammation and improve symptoms.

OBJECTIVE:

To assess efficacy and safety of povorcitinib (selective oral Janus kinase 1 inhibitor) in HS.

METHODS:

This placebo-controlled phase 2 study randomized patients with HS 1:1:1:1 to receive povorcitinib 15, 45, or 75 mg or placebo for 16 weeks. Primary and key secondary end points were mean change from baseline in abscess and inflammatory nodule count and percentage of patients achieving HS Clinical Response at week 16.

RESULTS:

Of 209 patients randomized (15 mg, n = 52; 45 mg, n = 52; 75 mg, n = 53; placebo, n = 52), 83.3% completed the 16-week treatment. At week 16, povorcitinib significantly reduced abscess and inflammatory nodule count from baseline (least squares mean [SE] change: 15 mg, -5.2 [0.9], P = .0277; 45 mg, -6.9 [0.9], P = .0006; 75 mg, -6.3 [0.9], P = .0021) versus placebo (-2.5 [0.9]). More povorcitinib-treated patients achieved HS Clinical Response at week 16 (15 mg, 48.1%, P = .0445; 45 mg, 44.2%, P = .0998; 75 mg, 45.3%, P = .0829) versus placebo (28.8%). A total of 60.0% and 65.4% of povorcitinib- and placebo-treated patients had adverse events.

LIMITATIONS:

Baseline lesion counts were mildly imbalanced between groups.

CONCLUSION:

Povorcitinib demonstrated efficacy in HS, with no evidence of increased incidence of adverse events among doses.

News (Medical) associated with Povorcitinib

01 Apr 2024

·www.biospace.com

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Povorcitinib, a selective oral JAK1 inhibitor discovered by Incyte, is an investigational medicine being evaluated for the treatment of non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria WILMINGTON, Del. and HONG KONG--(BUSINESS WIRE)-- Incyte Corporation (Nasdaq:INCY) (“Incyte”) and China Medical Systems Holdings Limited (“CMS” or the “Group”) are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology medical aesthetic subsidiary of the Company (“CMS Skinhealth”), entered into a Collaboration and License Agreement for the development and commercialization of povorcitinib (the “Product”), a selective oral JAK1 inhibitor, to research, develop, register and commercialize the Product in Mainland China, Hong Kong, Macao, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in CMS’ Territory. Under the terms of the agreement, CMS will make an upfront payment to Incyte and Incyte is eligible to receive additional potential development and commercial milestones and royalties on net sales of the licensed product in CMS’ territory. CMS will receive an exclusive license to develop and commercialize and a non-exclusive license to manufacture povorcitinib in autoimmune and inflammatory dermatologic diseases, including non-segmental vitiligo, hidradenitis suppurativa (HS), prurigo nodularis (PN), asthma and chronic spontaneous urticaria, for patients in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia. “We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” said Hervé Hoppenot, Chief Executive Officer, Incyte. “There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China.” Mr. Huang Anjun, the general manager of CMS Skinhealth, stated that, “We expect that this collaboration will enhance CMS Skinhealth's portfolio of potential treatments for vitiligo that, if approved, will provide differentiated treatment options for vitiligo patients in China. Upon approval, povorcitinib is poised to synergize with the innovative drugs in the commercialization stage of our pipeline Ilumetri (tildrakizumab injection), original/drugs including Hirudoid (mucopolysaccharide polysulfate cream) and Aethoxysklerol (polidocanol injection) in terms of our network and market resources, which will help the Product to realize its clinical and commercial value.” The transaction is effective immediately upon the execution of the Collaboration and License Agreement. About Povorcitinib Povorcitinib is a selective oral small-molecule JAK1 inhibitor, with compound and use patents in certain countries/regions in the Territory. Currently, povorcitinib is in Phase 3 clinical trials for non-segmental vitiligo and HS in multiple countries outside of China. Additionally, Phase 2 clinical studies of povorcitinib for PN, asthma and chronic spontaneous urticaria are also ongoing. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It is estimated that there are approximately 14 million vitiligo patients in China and 6.5 million in the eleven Southeast Asian countries respectively. Non-segmental vitiligo patients account for approximately 85% of them1. Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 302. Currently, therapeutic options for vitiligo are limited, and the condition is difficult to treat, especially for patients with moderate to severe extensive vitiligo. About Hidradenitis Suppurativa (HS) HS is a chronic recurrent inflammatory skin condition characterized by the presence of painful inflammatory nodules, abscesses, ruptures, as well as the formation of sinus tracts and scarring. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS3. It is estimated that there are approximately 470 thousand HS patients in China, about 75% of whom are moderate to severe patients4. Additionally, it is estimated that there are approximately 13 thousand HS patients in the six Southeast Asian countries, comprising Thailand, Singapore, Malaysia, Philippine, Vietnam and Indonesia. HS has been included in the second batch of the Rare Disease List in China. Given the debilitating nature of condition, it can have a profoundly negative effect on patients’ quality of life. However, currently in China, there are no biologics or small molecule medicines approved by the National Medical Products Administration for the treatment of HS, creating an urgent need for effective therapeutic options5. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. About CMS Skinhealth CMS’s Dermatology and Medical Aesthetic Business "CMS Skinhealth" regards dermatology prescription products as its core, and extends to dermatology-grade skincare products and light medical aesthetic products, continually optimizing full lifecycle skin-health management solutions, and gradually moving toward becoming "the largest and most professional skin-health management company in China ". Relying on its strong clinical development and commercialization advantages, CMS will realize the commercialization of povorcitinib in the Territory as soon as possible to meet the clinical needs of oral vitiligo drugs with efficacy and benefit relevant patients. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding whether and when povorcitinib will be approved for use in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; whether and when CMS will bring povorcitinib to market in mainland China, Hong Kong, Macau, Taiwan or Southeast Asia; the potential of povorcitinib to treat patients with vitiligo, hidradenitis superativa or for any other indication; the potential for Incyte to receive royalties and payments from CMS for development and commercial milestones; and the potential for Incyte to broaden its ability to bring new medicines to patients in Asia and elsewhere, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; Incyte’s dependence on its relationships with its collaboration partners; the efficacy or safety of Incyte’s products and the products of its collaboration partners; the acceptance of Incyte’s products and the products of its collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended December 31, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements. CMS Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. This press release may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of or any omission from this press release is expressly excluded. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. The Group assumes no obligation to update any forward-looking information contained in this press release. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. References： Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015 Jul 4;386(9988):74-84. doi: 10.1016/S0140-6736(14)60763-7. Epub 2015 Jan 15. PMID: 25596811 Frisoli M, et al. Vitiligo: mechanisms of pathogenesis and treatment. Annu. Rev. Immunol. 2020;38(1):621-648 Solimani, F., Meier, K., & Ghoreschi, K. (2019). Emerging topical and systemic JAK inhibitors in dermatology. Frontiers in immunology, 10, 2847 Prevalence of Acne Inversa (Hidradenitis Suppurativa) in China: A Nationwide Cross-Sectional Epidemiological Study Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement（2021 version）

License out/inPhase 3Phase 2

11 Mar 2024

·www.fiercepharma.com

Incyte's JAK cream Opzelura proves its worth in treating hidradenitis suppurativa in midstage study

Opzelura is a cream version of Incyte's blockbuster Jakafi. After a pair of approvals in recent years and as its sales continue to climb, Incyte's topical JAK inhibitor Opzelura is adding to its clinical case with trial results that demonstrate its benefits in patients with mild to moderate hidradenitis suppurativa (HS). In a phase 2 study testing twice-daily Opzelura cream in patients with mild to moderate HS, investigators noted a “significantly greater” reduction in patients’ abscesses and inflammatory nodule (AN) count after 16 weeks compared with patients who received a control cream. The disease is characterized by painful nodules and abscesses that can cause irreversible tissue destruction and scarring. The results, which the company shared in a presentation at this year’s American Academy of Dermatology meeting, show “great potential” for patients with milder HS, Incyte's vice president of inflammation and autoimmunity, Jim Lee, M.D., Ph.D., said in a release. “Despite its daily impact on the lives of patients, there are currently no approved therapies for mild-to-moderate HS and the current standard of care is often inadequate,” Lee added. “Today’s data represent an important step in progressing research for HS with the goal of being able to provide patients with an effective option to better manage their condition.” The drug reduced total AN count by 50% or more in roughly 79% of patients, while more than 20% of patients who received the drug achieved complete clearance. Plus, the majority of Opzelura patients met the criteria for Hidradenitis Suppurativa Clinical Response, a measure that includes a 50% or greater reduction in AN count without an increase in abscesses or draining fistulas. Two patients did discontinue their participation in the study, but no serious treatment-emergent adverse events were reported, Incyte said. Opzelura is a cream version of Incyte’s blockbuster Jakafi and scored its original approval in 2021 for atopic dermatitis, adding on an indication for vitiligo the following year. The med is currently the only topical JAK inhibitor on the U.S. market, but Leo Pharma and its contender delgocitinib stand to put pressure on Incyte’s dominance. Recently, the company has been steadily reporting positive phase 3 studies of its JAK inhibitor cream in chronic hand eczema. Elsewhere in Incyte’s JAK inhibitor arsenal is its oral povorcitinib, which just showed significant improvements in itch and disease severity in a phase 2 study in prurigo nodularis. Opzelura is also being tested in prurigo nodularis and is proving to be a rising star for Incyte. The drug brought in $338 million in 2023 sales as “one of the best recent dermatology launches,” the company's North American general manager Barry Flannelly said on the company’s fourth-quarter and full-year earnings conference call.

Clinical ResultPhase 3Phase 2Drug Approval

11 Mar 2024

·www.biospace.com

Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease

Pictured: Incyte building in Wilmington, Delaware/iStock, Bo Shen Incyte is on target to potentially challenge Sanofi and Regeneron’s blockbuster injectable Dupixent with its oral JAK1 inhibitor for prurigo nodularis. The biopharma presented positive Phase II results at the American Academy of Dermatology annual meeting Sunday. Povorcitinib helped a significant number of patients in the study to achieve a four point or greater improvement on the itch Numerical Rating Scale (NRS4). Across the three dosing groups, 36% to 54% of patients had itch improvement compared to the 8% on placebo at week 16 of the study. Those in the highest dosage group of 75 mg achieved the NRS4 within a median time of 17 days. The drug also performed well in its secondary endpoint to achieve Investigator’s Global Assessment Treatment Success scores of 0 or 1 with a greater than 2-grade improvement from baseline. The treatment was considered well-tolerated with few discontinuations due to adverse events. Although cross-trial comparisons are not always accurate, the data suggests povorcitinib could be a comparable treatment for PN to Sanofi and Regeneron’s already-approved Dupixent. Prurigo nodularis (PN) is a chronic inflammatory disease of the skin characterized by intense itching and thickened bumps on the extremities and trunk. The itchy nodules are often the worst aspect of the condition. Stopping the itch is “imperative” to treat PN patients as the itching multiplies the nodules, Martin Metz, a professor of dermatology, said in a statement. A Phase III trial is in its planning stages for PN. The candidate is already in a late-stage trial for hidradenitis suppurative and vitiligo. Additional indications in Phase II studies include asthma and chronic spontaneous urticaria. If the oral JAK inhibitor is approved, it’ll enter the market to challenge Sanofi and Regeneron’s blockbuster. Already approved for PN plus four other conditions, Dupixent sales in 2023 reached nearly $11.6 billion. The drug is an injectable, compared to Incyte’s oral formulation for povorcitinib. In the company’s fourth quarter of 2023 earnings call last month, Incyte CMO Steven Stein said Dupixent’s prior approval provided the regulatory pathway “in terms of itch resolution and skin change resolution.” Stein also touted the once-daily oral convenience of povorcitinib. Incyte currently has a JAK inhibitor cream on the market—Opzelura—for eczema and nonsegmental vitiligo. Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.

Clinical ResultPhase 3Phase 2Drug Approval

100 Deals associated with Povorcitinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Nonsegmental vitiligo	Phase 3	US	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	BG	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	CA	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	FR	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	DE	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	HU	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	IT	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	PL	Incyte Corp.	27 Nov 2023
Nonsegmental vitiligo	Phase 3	GB	Incyte Corp.	27 Nov 2023
Hidradenitis Suppurativa	Phase 3	US	Incyte Corp.	19 Dec 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04818346 (AAD2024) Manual	Phase 2	-	171	Povorcitinib (age≤40 years)	kvjlvyojia(txjipyhgfe) = pqjjfxrcha nblzquienh (hxdsfwgyux )	Positive	10 Mar 2024
				Povorcitinib (age>40 years)	kvjlvyojia(txjipyhgfe) = yrbhnjyilf nblzquienh (hxdsfwgyux )
NCT05061693 (Corporate Publications) Manual	Phase 2	prurigo nodularis	146	Povorcitinib 15 mg	sjbrzsarkz(vixgiwfeov) = lqvlebhoog ibxkkchlog (frswnnkacm ) Met View more	Positive	10 Mar 2024
				Povorcitinib 45 mg	sjbrzsarkz(vixgiwfeov) = mjzhxphexc ibxkkchlog (frswnnkacm ) Met View more
NCT04818346 (Corporate Publications) Manual	Phase 2	Nonsegmental vitiligo	171	povorcitinib 15-to-75 mg	vbujgdhwct(mokshvherk) = vugrfcjoct fdxpyhfazc (gdptpbejga ) View more	Positive	11 Oct 2023
				povorcitinib 45 mg	vbujgdhwct(mokshvherk) = pxdfhrhmhj fdxpyhfazc (gdptpbejga ) View more
NCT04818346 (phase 2b, EADV2023)	Phase 2	Vitiligo Fitzpatrick skin types I - III	171	Povorcitinib 15 mg	xltyjbiude(zqicxpapwn) = guknuwohuq qvlltalsnz (hcdupsivks )	Positive	11 Oct 2023
				Povorcitinib 45 mg	xltyjbiude(zqicxpapwn) = doyndxqvrb qvlltalsnz (hcdupsivks )
EADV2023	Phase 2	-	209	Povorcitinib 15 mg	rwyebqphqn(fjsxegtxtd) = kkudhcaizo mztdatertc (dlxntscxma )	-	11 Oct 2023
				Povorcitinib 45 mg	rwyebqphqn(fjsxegtxtd) = wntpajpioo mztdatertc (dlxntscxma )
NCT04818346 (phase 2b, CTgov)	Phase 2	Nonsegmental vitiligo	171	placebo+povorcitinib (Placebo)	vxclczuskz(zowlmafpyv) = tqagqchqfp qqtixkkqml (vetoqrzban, ldencxtamx - wvaahzvoxe) View more	-	05 Jul 2023
				Povorcitinib (Povorcitinib 15 mg)	vxclczuskz(zowlmafpyv) = bdenvbbgjw qqtixkkqml (vetoqrzban, rplgnarfza - srkgtciuxc) View more
NCT04476043 (CTgov)	Phase 2	Hidradenitis Suppurativa	209	INCB054707 (INCB054707 15 mg)	mgcgvdmnqj(vcsrbdisxc) = vmbvxtvtke gzuorjertn (ewutwcyldm, doeqoxljne - tiqdqjmxke) View more	-	26 Jan 2023
				INCB054707 (INCB054707 45 mg)	mgcgvdmnqj(vcsrbdisxc) = suqxdzscjs gzuorjertn (ewutwcyldm, ringydeotn - jmstzamdvr) View more
NCT04476043 (EADV2022)	Phase 2	Hidradenitis Suppurativa	209	INCB054707 15 mg	phssspfhef(mrvfllzyew) = 65.4% of placebo- and 60.0% of INCB054707-treated pts (15 mg, 59.6%; 45 mg, 60.0%; 75 mg, 60.4%) reported any TEAE gkhrvfywbc (vqpelcyjau ) View more	-	07 Sep 2022
				INCB054707 45 mg
NCT03569371 (Pubmed \| Br J Dermatol) Manual	Phase 2	Hidradenitis Suppurativa	45	Povorcitinib	qlxgdfsfgl(epakzpabvd) = mxqblrgjrg wwmosswmhc (ruabzmdfrc ) View more	Positive	02 Jan 2022
NCT03607487 (CTgov)	Phase 2	Hidradenitis Suppurativa	35	INCB54707 (INCB54707)	sramxwfxvi(uambasnkcd) = faultfsmpj iqchyzqqlb (ifyuyztbat, rrycfsrsyz - ldhxorevdp) View more	-	21 Sep 2020
				Placebo (Placebo)	mebetjufxv(pepvycvuzw) = azgatsayhm xcvahaymwa (ufgzlasawt, kffhbiqyyz - tcggbrghfe) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Povorcitinib

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation